ASCO 2023 | I-SPY2.2: emerging biomarkers in breast cancer

Denise Wolf, MD PhD, University of California, San Francisco, CA, discusses the impact of the ongoing I-SPY2.2 trial (NCT01042379) of neoadjuvant therapy in early-stage breast cancer. The adaptive trial aims to refine the response predictive subtyping (RPS) of early breast cancer. Dr Wolf shares that clinical trials are currently testing the early results of I-SPY2, for example, the study of immune agents in the HR+ subset of breast cancer. This interview took place during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved